Singular Genomics Systems, Inc. (NASDAQ:OMIC) CEO Andrew Spaventa Purchases 43,468 Shares of Stock

Singular Genomics Systems, Inc. (NASDAQ:OMICGet Free Report) CEO Andrew Spaventa bought 43,468 shares of the firm’s stock in a transaction that occurred on Thursday, November 16th. The stock was bought at an average cost of $0.41 per share, for a total transaction of $17,821.88. Following the completion of the acquisition, the chief executive officer now owns 3,986,206 shares in the company, valued at approximately $1,634,344.46. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Singular Genomics Systems Price Performance

Shares of NASDAQ:OMIC opened at $0.41 on Tuesday. The company has a market capitalization of $29.75 million, a P/E ratio of -0.32 and a beta of 0.98. Singular Genomics Systems, Inc. has a 1-year low of $0.31 and a 1-year high of $3.00. The firm’s 50 day simple moving average is $0.39 and its two-hundred day simple moving average is $0.65. The company has a debt-to-equity ratio of 0.05, a current ratio of 13.64 and a quick ratio of 15.15.

Institutional Trading of Singular Genomics Systems

Several institutional investors and hedge funds have recently modified their holdings of the company. Alliancebernstein L.P. bought a new position in Singular Genomics Systems in the 4th quarter worth $26,000. Balyasny Asset Management LLC bought a new position in shares of Singular Genomics Systems in the third quarter worth about $26,000. Millennium Management LLC purchased a new stake in shares of Singular Genomics Systems during the fourth quarter worth about $31,000. Cambridge Investment Research Advisors Inc. purchased a new stake in shares of Singular Genomics Systems during the first quarter worth about $32,000. Finally, Marino Stram & Associates LLC raised its stake in Singular Genomics Systems by 300.0% during the 2nd quarter. Marino Stram & Associates LLC now owns 40,000 shares of the company’s stock valued at $33,000 after purchasing an additional 30,000 shares during the period. 55.75% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, The Goldman Sachs Group decreased their price objective on Singular Genomics Systems from $1.15 to $1.00 and set a “neutral” rating on the stock in a research note on Thursday, August 10th.

Check Out Our Latest Analysis on Singular Genomics Systems

Singular Genomics Systems Company Profile

(Get Free Report)

Singular Genomics Systems, Inc, a life science technology company, develops next generation sequencing and multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables for applications comprising single cell gene expression and proteomics, in situ RNA sequencing, and spatial RNA and proteomics applications for tissue.

Featured Stories

Receive News & Ratings for Singular Genomics Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Singular Genomics Systems and related companies with's FREE daily email newsletter.